Many clinical trials support the occurrence of an over-expression of the pro-survival Bcl-2 protein, including a down-regulation of the pro-apoptotic Bax, as negative prognostic marker in patients with breast and other cancers [46]. This evidence concerns the gene BCL2 and cancer.